Table 2.
Clinic trials targeting ferroptosis in human diseases
| Human diseases or safety evaluation | Conditions | Interventions | NCT Number |
|---|---|---|---|
| Safety evaluation | Healthy Volunteers | BPM31510 (a lipid-drug conjugate nanodispersion) | NCT03002935, NCT02486055 |
| Coenzyme Q10 | NCT03429231, NCT05680857 | ||
| Deferiprone | NCT02465489, NCT02442310, NCT02189941, NCT01989455 | ||
| Deferasirox | NCT00419172, NCT00427505 | ||
| N-Acetylcysteine | NCT00552786, NCT01271088, NCT02723669, NCT02206178, NCT00434005 | ||
| Cancers | Breast Cancer | Coenzyme Q10 | NCT00976131, NCT00096356 |
| Hepatocellular Carcinoma | Coenzyme Q10 | NCT01964001 | |
| Melanoma | N-acetylcysteine | NCT01612221 | |
| Myeloid Leukemia | Deferasirox | NCT01273766 | |
| Pancreatic Cancer | BPM31510 | NCT02650804 | |
| Metabolic disorders | Acute Liver Failure | N-Acetylcysteine | NCT00004467, NCT00248625, NCT03679442, NCT02182167, NCT03759158, NCT01394497 |
| End Stage Liver Failure | N-Acetylcysteine | NCT00736541 | |
| Acute Lung Injury | N-Acetylcysteine | NCT00655928 | |
| Acute Renal Failure | N-Acetylcysteine | NCT01612013, NCT01907061, NCT00353340, NCT01467466, NCT00188630, NCT00187330, NCT01394419, NCT00736866, NCT02761577, NCT00356954, NCT00211653, NCT00122018 | |
| Chronic Kidney Disease | N-Acetylcysteine | NCT00498342, NCT00506506, NCT05264584, NCT01232257, NCT00572663, NCT04916080, NCT03636932 | |
| Coenzyme Q10 | NCT03579693 | ||
| End-Stage Renal Disease | N-Acetylcysteine | NCT00440869, NCT00188630, NCT00187330 | |
| Contrast-induced Nephropathy | N-Acetylcysteine | NCT01160627, NCT00497328, NCT00830193, NCT00492518, NCT00237614 | |
| Deferiprone | NCT01146925 | ||
| Kidney Transplantation | N-Acetylcysteine | NCT00851708 | |
| Alcoholic Hepatitis | N-Acetylcysteine | NCT03707951, NCT03216954, NCT03220776, NCT05840640, NCT00863785, NCT00962442, NCT00568087, NCT01214083 | |
| Diabetes | Coenzyme Q10 | NCT03111433, NCT02062034, NCT00703482 | |
| N-Acetylcysteine | NCT00493727, NCT00463671, NCT00915200, NCT00556465, NCT01265563, NCT01082445, NCT00337038, NCT01386645, NCT00188773, NCT02206152, NCT00609102, NCT01394510 | ||
| Hypercholesterolemia | Coenzyme Q10 | NCT06391606 | |
| Obesity | N-Acetylcysteine | NCT01550432, NCT02117700 | |
| Chronic Obstructive Pulmonary Disease | N-Acetylcysteine | NCT02818270, NCT01136239, NCT00969904, NCT03388853 | |
| Genetic disorders | Thalassemia | Amlodipine | NCT02065492 |
| Deferoxamine | NCT00000588, NCT00000595, NCT00000623, NCT00061750, NCT00733811, NCT00105495, NCT01369719 | ||
| Deferiprone | NCT03591575, NCT00733811 | ||
| Deferasirox | NCT00879242, NCT00171301, NCT00447694, NCT00061763, NCT01610297, NCT00105495, NCT01905774, NCT00901199, NCT00235391, NCT00560820, NCT03637556 | ||
| N-acetylcysteine | NCT04260516 | ||
| Non-transfusion Dependent Thalassemia | Deferasirox | NCT01709838 | |
| Hemosiderosis | Deferasirox | NCT00303329, NCT00631163, NCT02125877, NCT00673608, NCT01394029, NCT00845871 | |
| Deferiprone | NCT00350662, NCT00349453 | ||
| Desferrioxamine | NCT00350662, NCT00349453 | ||
| N-acetylcysteine | NCT02481609 | ||
| Transfusional Iron Overload | Deferiprone | NCT00529152, NCT03802916 | |
| Deferasirox | NCT01376622, NCT00654589, NCT01335035, NCT01874405, NCT03372083, NCT01838291, NCT01044186, NCT00379483, NCT00171210, NCT00600938, NCT00390858, NCT02435212, NCT00749515, NCT00171821 | ||
| Sickle Cell Anemia | Deferoxamine | NCT00067080 | |
| Deferasirox | NCT05392101, NCT00110617, NCT01090323 | ||
| Deferiprone | NCT01835496 | ||
| N-acetylcysteine | NCT01849016, NCT01800526 | ||
| Cystic Fibrosis | N-acetylcysteine | NCT00809094 | |
| Duchenne Muscular Dystrophy | Coenzyme Q10 | NCT01126697, NCT00033189 | |
| Idebenone | NCT00758225, NCT00654784, NCT01027884 | ||
| Freidreich's Ataxia | Deferiprone | NCT00530127, NCT00897221 | |
| EPI-743 (Vatiquinone, α-Tocotrienol quinone) | NCT01728064 | ||
| Idebenone | NCT00993967, NCT00078481, NCT00015808, NCT00905268, NCT00697073, NCT01303406 | ||
| Leber's Hereditary Optic Neuropathy | Idebenone | NCT00747487, NCT02771379, NCT02774005 | |
| Myelodysplastic Syndrome | Deferiprone | NCT02477631 | |
| Deferasirox | NCT00110266, NCT01250951, NCT00940602, NCT00564941, NCT00469560, NCT00117507, NCT00481143 | ||
| Cardiovascular diseases | Cardiac Arrest | Coenzyme Q10 | NCT01319110 |
| Cardiac Iron Overload | Deferasirox | NCT01254227 | |
| Deferoxamine | NCT01254227 | ||
| Diabetic Cardiomyopathy | Coenzyme Q10 | NCT02255682, NCT02115581 | |
| Hypertrophic Cardiomyopathy | N-acetylcysteine | NCT01537926 | |
| Myocardial Infarction | N-Acetylcysteine | NCT01218178, NCT01501110 | |
| Atherosclerosis | N-acetylcysteine | NCT02422927 | |
| Coenzyme Q10 | NCT00908297 | ||
| Coronary Artery Disease | Coenzyme Q10 | NCT01424761, NCT01163500, NCT00860847 | |
| N-acetylcysteine | NCT01021163 | ||
| Central nervous system diseases | Parkinson’s Disease | Coenzyme Q10 | NCT00076492, NCT01892176, NCT03061513, NCT00004731, NCT00180037 |
| Deferiprone | |||
| EPI-743 | NCT01923584 | ||
| N-acetylcysteine | NCT01470027, NCT02212678, NCT02445651, NCT01427517 | ||
| Huntington's Disease | Coenzyme Q10 | NCT00980694, NCT00920699 | |
| Autism Spectrum Disorder | N-acetylcysteine | NCT03008889, NCT00889538, NCT00676195, NCT00627705, NCT00453180 | |
| Depression | N-acetylcysteine | NCT02269540 | |
| Bipolar Depression | Coenzyme Q10 | ||
| N-acetylcysteine | NCT02294591, NCT02357290, NCT01797575, NCT05340504, NCT03730064 | ||
| Cannabis Dependence | N-acetylcysteine | NCT01005810, NCT00542750, NCT01675661, NCT03055377 | |
| Cocaine Abuse | N-acetylcysteine | NCT02141620, NCT00218491, NCT02994875, NCT02124941, NCT00136825, NCT03556371 | |
| Methamphetamine Abuse | N-acetylcysteine | NCT01063205, NCT00332605, NCT04405193 | |
| Nicotine Dependence | N-acetylcysteine | NCT00751257, NCT02723162, NCT02737358, | |
| Obsessive-compulsive Disorder | N-acetylcysteine | NCT01172275, NCT01555970 | |
| Neuropathic Pain | N-acetylcysteine | NCT01840345, NCT03354572 | |
| Coenzyme Q10 | NCT00997269 | ||
| Traumatic Brain Injury | N-acetylcysteine | NCT00724594, NCT01322009, NCT04291066, NCT01515839, NCT02791945 | |
| Cognitive Dysfunction | N-acetylcysteine | NCT00611897 | |
| Schizophrenia | N-acetylcysteine | NCT01506765, NCT01232790, NCT01885338, NCT02505477, NCT01339858, NCT03510741, NCT01354132 | |
| Dry Eye Syndrome | Coenzyme Q10 | NCT03074344 | |
| N-acetylcysteine | NCT01747616, NCT01753752, NCT01278784, NCT01015209 | ||
| Ischemia-reperfusion injury | Hepatectomy Reperfusion Injury | Deferasirox | NCT00432627 |
| N-acetylcysteine | NCT01223326, NCT00564642 | ||
| Hypoxic-ischemic Encephalopathy | N-acetylcysteine | NCT04643821 | |
| Musculoskeletal diseases | Amyotrophic Lateral Sclerosis | Deferiprone | NCT02164253 |
| Coenzyme Q10 | NCT00243932 | ||
| Skeletal Muscle Damage | N-acetylcysteine | NCT02930031, NCT04523675, NCT01778309 |